[
    {
        "file_name": "IMMUNOMEDICSINC_08_07_2019-EX-10.1-PROMOTIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "11.6.2 Company represents and warrants that it has implemented, and covenants that it will maintain during the Term, adequate systems, policies, and procedures governing (1) interactions with health care professionals, (2) material that can be distributed or discussed with health care professionals, (3) the manner in which personnel should handle unsolicited requests for off- label information, and (4) the review and approval of all marketing, promotion, and sales materials, call plans, and incentive compensation structures. Company represents and warrants that such policies and procedures are and will be consistent with applicable Law and with this Agreement.",
                "changed_text": "11.6.2 Company represents and warrants that it has implemented, and covenants that it will maintain during the Term, adequate systems, policies, and procedures governing (1) interactions with health care professionals, (2) material that can be distributed or discussed with health care professionals, (3) the manner in which personnel should handle unsolicited requests for off- label information, and (4) the review and approval of all marketing, promotion, and sales materials, call plans, and incentive compensation structures. Company makes no guarantees that such policies and procedures are and will be consistent with applicable Law and with this Agreement.",
                "explanation": "The original text asserts that the policies *will be* consistent with applicable law and the agreement. The modified text introduces uncertainty by stating that Company *makes no guarantees* about that consistency. This creates a contradiction, as one statement expresses assurance, while the other expresses lack of assurance regarding the same issue.",
                "location": "Section 11.6.2"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "11.6.3 Company represents and warrants that neither Company, nor any of its employees, officers, directors, or agents, has been debarred by the FDA, is the subject of a conviction described in 21 U.S.C. 335a, or is subject to any similar sanction. Company represents and warrants that it has not, and covenants that it will not engage, in any capacity in connection with this Agreement, any person who has been debarred by FDA, is the subject of a conviction described in 21 U.S.C. 335a, or is subject to any similar sanction. Company shall promptly inform Janssen in writing if it or any person performing services under this Agreement is debarred or is the subject of a conviction described in 21 U.S.C. 335a, or if any action, suit, claim, investigation, or legal or administrative proceeding is pending or threatened relating to the debarment or such conviction of Company or any such person performing services in connection with this Agreement. Upon written request from Janssen, Company shall, within ten (10) days, provide written confirmation that it has complied with the foregoing obligation.",
                "changed_text": "11.6.3 Company represents and warrants that neither Company, nor any of its employees, officers, directors, or agents, has been debarred by the FDA, is the subject of a conviction described in 21 U.S.C. 335a, or is subject to any similar sanction. Company represents and warrants that it has not, and covenants that it will not engage, in any capacity in connection with this Agreement, any person who has been debarred by FDA, is the subject of a conviction described in 21 U.S.C. 335a, or is subject to any similar sanction. Company is not required to inform Janssen in writing if it or any person performing services under this Agreement is debarred or is the subject of a conviction described in 21 U.S.C. 335a, or if any action, suit, claim, investigation, or legal or administrative proceeding is pending or threatened relating to the debarment or such conviction of Company or any such person performing services in connection with this Agreement. Upon written request from Janssen, Company shall, within ten (10) days, provide written confirmation that it has complied with the foregoing obligation.",
                "explanation": "The original text requires Company to *promptly inform* Janssen of any debarment or related issues. The changed text states that *Company is not required to inform* Janssen. This creates a direct contradiction about the obligation to provide notification, undermining Janssen's ability to ensure compliance.",
                "location": "Section 11.6.3"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "8.1.4 Material Breach. This Agreement may be terminated by either Party in the event that the other Party commits a material breach of this Agreement and (a) such breach shall not have been cured within thirty (30) days after the giving of notice of such material breach, unless (i) the specific provision to which such breach relates expressly provides for a different period, or (ii) the Parties mutually agree in writing to an extension of such period (the \"Cure Period\"); or (b) such breach, by its nature, is not curable. Unless such breach in clause (a) is cured during the Cure Period, such termination will be effective immediately upon the expiration of the Cure Period without any further action or notice by the non-breaching Party. In the case of a breach in clause (b), such termination will be effective thirty (30) days following written notice of such breach being given to the breaching Party.",
                "changed_text": "8.1.4 Material Breach. This Agreement may be terminated by either Party in the event that the other Party commits a material breach of this Agreement and (a) such breach shall not have been cured within thirty (30) days after the giving of notice of such material breach, unless (i) the specific provision to which such breach relates expressly provides for a different period, or (ii) the Parties mutually agree in writing to an extension of such period (the \"Cure Period\"); or (b) such breach, by its nature, is not curable. Unless such breach in clause (a) is cured during the Cure Period, such termination will be effective thirty days upon the expiration of the Cure Period without any further action or notice by the non-breaching Party. In the case of a breach in clause (b), such termination will be effective immediately following written notice of such breach being given to the breaching Party.",
                "explanation": "In this perturbation, it is observed that there is a change in time for the breach by its nature, is not curable. In the original text it indicated thirty days following written notice of such breach being given to the breaching party, and that was changed to immediately following written notice of such breach being given to the breaching party. This introduces uncertainty in enforcement.",
                "location": "Section 8.1.4"
            }
        ]
    }
]